APG101 in Myelodysplastic Syndrome

Summary

It has been shown in preclinical experiments with bone marrow from patients with myelodysplastic syndrome that APG101 rescues erythrocytes from premature cell death. This is expected to translate in an improved erythropoiesis and ameliorated anemia in MDS patients. APG101 might, therefore, be a valuable addition to current treatments of low- or intermediate MDS patients suffering from anaemia. Transfusion-dependent patients with low or intermediate risk MDS according to WHO Prognostic Scoring Scale (WPSS) can be included in this study. Treatment consists of 100mg APG101 intravenous as a weekly treatment over 12 weeks + 6 months follow up phase. Primary objective of the trial is safety and tolerability of APG101; secondary objectives are * Hematologic, cytologic and cytogenetic response rate using modified International Working Group (IWG) response criteria * Incidence and time to leukemic progression at 37 weeks * OS (Overall survival) at 37 weeks

Timeline

Start

2013-01

Primary completion

2015-12

Completion

2015-12

Drugs

Indications